Modification of Contract No. 2, dated July 29, 2021, between Paratek Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services

Exhibit 10.2

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

103912510_9

103912510_9

SUMMARY OF CHANGES

Beginning with the effective date of this modification, the Government and Contractor mutually agree as follows:

ARTICLE B.3. OPTIONS is modified to incorporate CLIN 0009 as follows:

103912510_9

ARTICLE B.4. ADVANCE UNDERSTANDINGS is modified as follows:

m. VMI

[***]

ARTICLE C.1. STATEMENT OF WORK is modified as follows:

Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities not otherwise provided by the Government as needed to perform the Statement of Work dated July 22, 2021 set forth in SECTION J - List of Attachments, attached hereto and made a part of the contract.

SECTION J - LIST OF ATTACHMENTS is modified as follows:

1.Statement of Work, dated July 22, 2021, 11 pages

2.Invoice/Financing Instructions for Cost-Reimbursement Type Contracts

3.Invoice Instructions for Fixed-Priced Type Contracts

4.Sample Invoice Form

5.Report of Government Owned, Contractor Held Property, 1 page

6.Form SF-LLL, Disclosure of Lobbying Activities, 2 pages

7.Paratek Intellectual Property, 20 Pages

103912510_9

8.VMI[***] Requirements, 3 Pages

9.Vendor Managed Inventory Plan v.1, 14 Pages

All other terms and conditions of this contract remain unchanged and in full force and effect.

END OF MODIFICATION P00002 to 75A50120C00001

103912510_9

ATTACHMENT 1

Statement of Work
75A50120C00001

Date: 7-22-2021

PREAMBLE

Independently and not as an agency of the Government, the Contractor shall be required to furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government, as needed to perform the Statement of Work.

The Government reserves the right to modify the milestones, progress, schedule, budget, or deliverables to add or delete deliverables, process, or schedules if the need arises. Because of the nature of this research and development (R&D) contract and the complexities inherent in this and prior programs, at designated milestones the Government will evaluate whether work should be redirected, removed, or whether schedule or budget adjustments should be made. The Government reserves the right to change the product, process, schedule, or events to add or delete part or all of these elements as the need arises.

Overall Objectives and Scope

The overall objective of this contract is to procure an antibiotic that can be used under Emergency Use Authorization (EUA) pre-approval or marketing authorization for the treatment and/or post-exposure prophylaxis treatment of pulmonary anthrax. The Contractor will develop NUZYRA® for Animal Rule licensure, with the objective of making it suitable for stockpiling and use to treat infections with B. anthracis. Once suitable regulatory authorization has been achieved or under an applicable stockpiling authority, NUZYRA® will be purchased and delivered to the [***] or these supplies will become part of a VMI program managed by Paratek. Optional objectives cover activities to help secure the NUZYRA® supply chain, activities to support the commercial sustainability of NUZYRA® with the objective to ensuring continued supply, activities intended to expand the Animal Rule licenses of NUZYRA®, and further purchases for VMI managed by Paratek. The scope of work for this contract includes preclinical, clinical, manufacturing and procurement activities that fall into the following areas: nonclinical activities; clinical activities; manufacturing activities; procurement activities and all associated regulatory, quality assurance, management, and administrative activities. The Research and Development (R&D) efforts and procurement of NUZYRA® will progress in specific stages that cover the base performance (CLINs 1 and 2) segment and six (6) option segments (CLINs 3 to 8) as specified in this contract. The Contractor must complete specific tasks required in each of the discrete work segments. The scope of work has been broken into the following phases which are discrete work segments:

Page 1 of 11

103912510_9

The Contractor will continue to develop of NUZYRA® for the treatment of pulmonary Anthrax with the objective of obtaining approval through the FDA Animal Rule.

[***]

The Contractor will supply 2,500 drug product treatment courses of NUZYRA® [***]

[***]

[***]

[***]

[***]

Page 2 of 11

103912510_9

The Contractor shall store and maintain under the recommended storage conditions purchased NUZYRA® drug product inventory for the US Government in a VMI or deliver such inventory to the ASPR[***] in the manner described in CLIN 2.

The Contractor shall store and maintain under the recommended storage conditions purchased NUZYRA® drug product inventory for the US Government in a VMI or deliver such inventory to the ASPR[***] in the manner described in CLIN 2.

The Contractor shall store and maintain under the recommended storage conditions purchased NUZYRA® drug product inventory for the US Government in a VMI or deliver such inventory to the ASPR[***] in the manner described in CLIN 2.

The Contractor is to be prepared to deploy up to [***] treatment courses of drug product from existing product in VMI to the field in the United States in the event of a national emergency or a small scale emergency situation under an appropriate regulatory mechanism (e.g. EUA, IND or sNDA), following the agreed upon procedures between Contractor, BARDA[***]

Page 3 of 11

103912510_9

Revised Timeline view of all CLINs provided in the SOW (3/26/2020)

[***]

Page 4 of 11

103912510_9

103912510_9

ATTACHMENT 9

CLIN0002 Vendor Managed Inventory Plan for Paratek Pharmaceuticals

[Pursuant to Regulation S-K, Item 601(a)(5), this Attachment 9 setting forth the Vendor Managed Inventory Plan has not been filed.  The Registrant agrees to furnish supplementally a copy of any omitted scheduled to the Securities and Exchange Commission upon request; provided, however, that the Registrant may request confidential treatment of omitted items.]

[***]

103912510_9